Last reviewed: July 7, 2026
Last updated: July 7, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
The weight loss market offers many biochemical pathways, but not all produce equal results. NAD+ boosters and GLP-1 receptor agonists like semaglutide target fundamentally different mechanisms—and clinical evidence strongly favors semaglutide for sustained weight reduction. Understanding this distinction helps patients choose therapies aligned with their metabolic goals.
How NAD+ Affects Metabolism and Weight
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. It plays a central role in energy production by helping cells convert nutrients into usable ATP. When NAD+ levels decline with age, cellular energy metabolism becomes less efficient, potentially contributing to weight gain and reduced metabolic rate. NAD+ boosters like NMN and NR aim to restore these levels.
Some animal studies suggest NAD+ enhancement may improve mitochondrial function and increase metabolic rate by 5–10%. However, human clinical trials testing NAD+ for weight loss remain limited. Most NAD+ research focuses on aging and longevity rather than fat loss itself. The current evidence base does not demonstrate that NAD+ supplementation alone produces meaningful or sustained weight reduction in overweight populations.
Semaglutide's Direct Action on Appetite and Blood Sugar
Semaglutide is a GLP-1 receptor agonist that binds to appetite-regulating centers in the brain and slows stomach emptying. This mechanism directly suppresses hunger signals, reduces food cravings, and increases feelings of fullness. Unlike NAD+, which supports general cellular function, semaglutide addresses the specific neural and hormonal pathways driving overeating and weight gain.
Clinical trials demonstrate that semaglutide produces 15–22% body weight reduction over 68 weeks in people with obesity. The STEP trials showed that semaglutide achieved meaningful weight loss in real-world populations, with improvements in cardiometabolic risk factors including blood pressure, cholesterol, and glucose control. These outcomes far exceed what NAD+ supplementation alone has demonstrated in published literature.
Why Semaglutide Outperforms NAD+ for Weight Management
Semaglutide's superiority for weight loss stems from its direct targeting of hunger circuits and metabolic regulation. While NAD+ supports cellular efficiency broadly, it does not reduce appetite or improve satiety signals. A person with high NAD+ levels but dysregulated hunger hormones will still struggle to maintain a caloric deficit. Semaglutide removes that barrier by modulating the brain regions and hormones controlling food intake.
Additionally, semaglutide improves insulin sensitivity and glucose homeostasis, which NAD+ does not directly address. This dual mechanism—appetite suppression plus better blood sugar control—creates a compound metabolic advantage. Patients using semaglutide report sustained weight loss, improved energy, and reduced carbohydrate cravings within 4–8 weeks of starting therapy.
PlexusDx offers compounded semaglutide injection from licensed 503A pharmacies, starting at just $149 per month with no insurance required. This pricing reflects PlexusDx's commitment to making evidence-based weight loss accessible, without the expense of brand-name Wegovy.
Personalization: Genetic Testing Reveals Your Peptide Pathway
Individual responses to semaglutide vary based on genetic predisposition to GLP-1 sensitivity. PlexusDx Precision Peptide Genetic Test analyzes key variants in the GLP1R gene (rs6923761), GIPR pathway (rs1800437), and metabolic genes like FTO (rs9939609) and MC4R (rs17782313). This genetic mapping reveals whether your body is naturally responsive to GLP-1 therapy or may require alternative compounds like tirzepatide.
The test examines 14 signaling pathways and 150+ genetic insights related to appetite, satiety, and peptide sensitivity. By matching your genetic profile to the right therapy—whether semaglutide, tirzepatide, or a dual compound—PlexusDx maximizes your probability of success. NAD+ supplementation offers no such personalization, making it a one-size-fits-all approach that ignores your unique biochemistry.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I take NAD+ and semaglutide together?
Yes, there are no known drug interactions between NAD+ boosters and semaglutide. However, combining them serves no additional weight loss benefit. Semaglutide alone produces the documented clinical results; NAD+ supplementation would add cost without evidence-based improvement. A PlexusDx provider can assess your full regimen during your consultation.
How quickly does semaglutide work compared to NAD+?
Semaglutide users typically notice reduced hunger and improved food choices within 4–7 days of the first dose. Most experience meaningful weight loss (5–10 lbs) by week 4. NAD+ supplementation has no established timeline for weight loss because clinical trials in overweight populations are sparse. Semaglutide's rapid appetite suppression is a distinct advantage for patients seeking quick metabolic shifts.
How much does PlexusDx semaglutide cost versus Wegovy?
PlexusDx compounded semaglutide injection starts at $149 per month with no insurance required and no membership fees. Wegovy typically costs $900–$1,200 monthly with insurance or $1,350+ without coverage. PlexusDx's transparent pricing means your dose may increase, but your price won't. All medications come from licensed 503A compounding pharmacies and are HSA/FSA eligible.
Are there side effects from semaglutide that NAD+ doesn't cause?
Semaglutide can cause nausea, vomiting, or mild stomach discomfort, especially at higher doses—side effects NAD+ typically does not produce. However, these effects are usually transient and manageable, resolving within 2–3 weeks as your body adjusts. PlexusDx providers work with you to optimize dosing and manage any symptoms. The clinical benefits consistently outweigh these temporary adjustments for most patients.
Can the Precision Peptide Genetic Test predict if NAD+ will work for me?
The PlexusDx Precision Peptide Genetic Test does not assess NAD+ metabolism—it is specifically designed to map your GLP-1, GIPR, and metabolic peptide pathways. This test identifies your genetic responsiveness to semaglutide, tirzepatide, and other GLP-1 therapies, enabling truly personalized treatment selection. If you are a poor responder to GLP-1 therapy, the test can guide your provider toward tirzepatide or dual-compound options instead.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Is Zepbound an Injection or Pill? Understanding This New Weight Loss Medication
What is Better: Weight Loss with Ozempic or Wegovy?